soul trial oral semaglutide cardiovascular outcomes 2024 nejm results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM soul trial oral semaglutide cardiovascular

We strongly encourage you to speak to a healthcare provider to assess if this type of treatment is appropriate for your unique needs

"I love those stupid things, and suddenly they taste like potato-shaped metal chunks." The poster also said a doughnut was bitter

Overall, while FGF21-based therapies represent a promising class, further phase 3 data are needed to define their long-term clinical benefit, optimal patient selection, and positioning relative to other metabolic and antifibrotic therapies

Short-acting GLP-1RAs slow down stomach emptying more than long-acting ones [2]

Co-authors: Phil Baker, PharmD Send download link to: If one pharmacist calls another and asks if they have any of this years most popular drug, they dont even have to say a name